zedie.wordpress.com
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. …